Department of Psychiatry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Phytother Res. 2021 Dec;35(12):6585-6606. doi: 10.1002/ptr.7243. Epub 2021 Aug 18.
Recent studies have reported conflicting findings on the antianxiety, antidepressant, and anti-stress properties of Rosa Damascena Mill (RDM). Therefore, the present systematic review and meta-analysis were conducted on the effects of RDM for treating anxiety, depression, and stress amongst adults. The online data sources of Cochrane Central Register of Controlled Trials, PubMed, Scopus, Web of Science, Embase, ProQuest, and Scientific Information Database were searched from inception to June 30, 2021. The randomized controlled trials (RCTs), which examined the effects of RDM (in any form of administration) on adults' anxiety, depression, and stress, were included. A random-effects model was applied to pool the data, and a total of 32 publications were included. The results of the meta-analysis revealed that administration of RDM significantly reduced state anxiety (effect size [ES]: 24, standardized mean difference [SMD]: -1.74, 95% confidence interval [CI]: -2.29, -1.20; p < .001), depression (ES: 7, SMD: -0.87, 95% CI: -1.47, -0.28; p = .004), and stress (ES: 4, SMD: -1.33, 95% CI: -1.98, -0.69; p < .001). However, the treatment had no significant effect on trait anxiety (ES: 6, weighted mean difference: -0.75, 95% CI: -1.93, 0.43; p = .214). The association between the total administration dosage and/or duration of RDM and the changes in state anxiety and depression was not dose-dependent. Most RCTs had a fair methodological quality based on the Cochrane risk of bias assessment tool. Besides, the quality of evidence ranged from very low to moderate according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Hence, further high-quality RCTs are needed to draw reliable conclusions regarding the use of RDM for treating adults' anxiety, depression, and stress.
最近的研究报告对大马士革玫瑰（Rosa Damascena Mill，RDM）的抗焦虑、抗抑郁和抗应激特性的结果存在矛盾。因此，本系统评价和荟萃分析旨在评估 RDM 治疗成人焦虑、抑郁和应激的效果。从研究开始到 2021 年 6 月 30 日，检索了 Cochrane 对照试验中心注册库、PubMed、Scopus、Web of Science、Embase、ProQuest 和科学信息数据库等在线数据资源。纳入了评估 RDM（任何给药形式）对成人焦虑、抑郁和应激影响的随机对照试验（RCT）。采用随机效应模型对数据进行合并，共纳入 32 篇文献。荟萃分析结果表明，给予 RDM 可显著降低状态焦虑（效应量[ES]：24，标准化均数差[SMD]：-1.74，95%置信区间[CI]：-2.29，-1.20；p<0.001）、抑郁（ES：7，SMD：-0.87，95%CI：-1.47，-0.28；p=0.004）和应激（ES：4，SMD：-1.33，95%CI：-1.98，-0.69；p<0.001）。然而，该治疗对特质焦虑无显著影响（ES：6，加权均数差：-0.75，95%CI：-1.93，0.43；p=0.214）。RDM 的总给药剂量和/或持续时间与状态焦虑和抑郁变化之间的关联不是剂量依赖性的。大多数 RCT 根据 Cochrane 偏倚风险评估工具具有良好的方法学质量。此外，根据推荐评估、制定和评价（GRADE）方法，证据质量从极低到中等。因此，需要进一步开展高质量 RCT 来得出关于 RDM 治疗成人焦虑、抑郁和应激的可靠结论。
